Merck KGaA’s Bavencio And Mavenclad Growth Steal Show During Q2 Earnings
With Double-Digit Growth
Executive Summary
Sky-high sales growth of the German major’s Bavencio and Mavenclad caught the eye of some observers as the firm continues to advance these drugs in new disease settings to unlock their full potential.
You may also be interested in...
Sanofi’s MS Candidate Tolebrutinib On Clinical Hold Following Liver Toxicities
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.
Merck KGaA Boosted By Bavencio, Mavenclad And COVID Vaccine Fees
The German group's efforts in helping its peers in the industry with their respective COVID-19 vaccines have been rewarded with strong revenue growth while its own newer drugs beat analyst forecasts.
Merck Takes A New Shot At Alzheimer’s With Cerevance Deal
The major will use the biotech’s brain cell-focused platform technology to discover new targets for Alzheimer’s disease.